## Zonghui Hu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/237164/publications.pdf

Version: 2024-02-01

47 2,971 22 papers citations h-index

22 41
h-index g-index

47 47 all docs citations

47 times ranked 4978 citing authors

#	Article	IF	CITATIONS
1	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science Translational Medicine, 2015, 7, 319ra206.	12.4	390
2	A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. New England Journal of Medicine, 2017, 376, 330-341.	27.0	314
3	Chimpanzee Adenovirus Vector Ebola Vaccine. New England Journal of Medicine, 2017, 376, 928-938.	27.0	243
4	Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet, The, 2018, 391, 552-562.	13.7	235
5	Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet, The, 2014, 384, 2046-2052.	13.7	206
6	A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus–associated cryoglobulinemic vasculitis. Arthritis and Rheumatism, 2012, 64, 835-842.	6.7	204
7	DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infectious Diseases, The, 2011, 11, 916-924.	9.1	174
8	Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Medicine, 2018, 15, e1002493.	8.4	174
9	Immune regulation by glucocorticoids can be linked to cell type–dependent transcriptional responses. Journal of Experimental Medicine, 2019, 216, 384-406.	8.5	130
10	HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19851-19856.	7.1	111
11	Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet, The, 2015, 385, 1545-1554.	13.7	109
12	A Monoclonal Antibody for Malaria Prevention. New England Journal of Medicine, 2021, 385, 803-814.	27.0	95
13	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV,the, 2019, 6, e667-e679.	4.7	67
14	Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. Aids, 2011, 25, 1727-1735.	2.2	44
15	Profile-kernel versus backfitting in the partially linear models for longitudinal/clustered data. Biometrika, 2004, 91, 251-262.	2.4	43
16	Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance. Blood, 2011, 118, 3244-3253.	1.4	41
17	Serum tryptase levels in atopic and nonatopic children. Journal of Allergy and Clinical Immunology, 2009, 124, 845-848.	2.9	40
18	Overcoming Allelic Specificity by Immunization with Five Allelic Forms of Plasmodium falciparum Apical Membrane Antigen 1. Infection and Immunity, 2013, 81, 1491-1501.	2.2	40

#	Article	IF	CITATIONS
19	Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation. PLoS ONE, 2016, 11, e0167091.	2.5	38
20	Semiparametric dimension reduction estimation for mean response with missing data. Biometrika, 2010, 97, 305-319.	2.4	32
21	Evaluation of the Performance of the Sysmex XT-2000i Hematology Analyzer With Whole Blood Specimens Stored at Room Temperature. Laboratory Medicine, 2009, 40, 709-718.	1.2	30
22	Chronic Exposure to Type-I IFN under Lymphopenic Conditions Alters CD4 T Cell Homeostasis. PLoS Pathogens, 2014, 10, e1003976.	4.7	24
23	New Methods for Treatment Effect Calibration, with Applications to Non-Inferiority Trials. Biometrics, 2016, 72, 20-29.	1.4	23
24	Glucocorticoid-induced eosinopenia results from CXCR4-dependent bone marrow migration. Blood, 2020, 136, 2667-2678.	1.4	23
25	Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults. PLoS ONE, 2015, 10, e0123969.	2.5	22
26	Estimation of mean response via the effective balancing score. Biometrika, 2014, 101, 613-624.	2.4	19
27	ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. Journal of Medical Virology, 2012, 84, 1106-1114.	5.0	15
28	Plasma Interleukin-27 (IL-27) Levels Are Not Modulated in Patients with Chronic HIV-1 Infection. PLoS ONE, 2014, 9, e98989.	2.5	14
29	Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach. Aids, 2008, 22, 1433-1439.	2.2	11
30	Semiparametric Double Balancing Score Estimation for Incomplete Data With Ignorable Missingness. Journal of the American Statistical Association, 2012, 107, 247-257.	3.1	10
31	Generalizability of causal inference in observational studies under retrospective convenience sampling. Statistics in Medicine, 2018, 37, 2874-2883.	1.6	10
32	Dimension reduced kernel estimation for distribution function with incomplete data. Journal of Statistical Planning and Inference, 2011, 141, 3084-3093.	0.6	8
33	Comparison of the Abbott 7000 and Bayer 340 Systems for Measurement of Hepatitis C Virus Load. Journal of Clinical Microbiology, 2007, 45, 2808-2812.	3.9	6
34	Noninferiority Trial Design and Analysis with an Ordered Three-Level Categorical Endpoint. Journal of Biopharmaceutical Statistics, 2009, 19, 685-699.	0.8	6
35	Vaccine design via nonnegative lassoâ€based variable selection. Statistics in Medicine, 2015, 34, 1791-1798.	1.6	6
36	Twoâ€part test of vaccine effect. Statistics in Medicine, 2015, 34, 1904-1911.	1.6	5

3

#	Article	IF	CITATIONS
37	A nonparametric likelihood test for detecting discordance between two measurements with application to censored viral load determinations. Statistics in Medicine, 2008, 27, 4489-4501.	1.6	3
38	Semiparametric Two-Sample Changepoint Model with Application to Human Immunodeficiency Virus Studies. Journal of the Royal Statistical Society Series C: Applied Statistics, 2008, 57, 589-607.	1.0	2
39	Estimating the Population Average Treatment Effect in Observational Studies with Choice-Based Sampling. International Journal of Biostatistics, 2019, 15, .	0.7	2
40	Assessing conditional causal effect via characteristic score. Statistics in Medicine, 2021, 40, 5188-5198.	1.6	1
41	Semiparametric mixture survival model with application to MRFIT study. Statistics and Its Interface, 2014, 7, 19-26.	0.3	1
42	Statistical methods for active extension trials. Statistics in Medicine, 2007, 26, 2433-2448.	1.6	0
43	Semiparametric pseudoscore for regression with multidimensional but incompletely observed regressor. Statistics in Medicine, 2018, 37, 207-217.	1.6	0
44	Temporal trends of biomarkers and betweenâ€biomarker associations. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 251-264.	1.0	0
45	Semiparametric latent covariate mixed-effects models with application to a colon carcinogenesis study. Statistics and Its Interface, 2008, 1, 75-86.	0.3	0
46	Comparison of serum and urinary concentrations of clenbuterol with and without concomitant administration of furosemide in horses. Veterinary Therapeutics: Research in Applied Veterinary Medicine, 2002, 3, 316-25.	0.3	0
47	A mixture distribution approach for assessing genetic impact from twin study. Statistics in Medicine, 2022, , .	1.6	0